Here are eight observations:
1. Analysts predict the market will grow at a 5.7 percent compound annual growth through 2022.
2. Although the open spine surgery segment captured the highest revenue in the market in 2015, the minimally invasive spine surgery market is supposed to grow at the highest CAGR through 2022.
3. The increasing adoption of minimally invasive spine surgery as well as the growing number of osteoporosis and arthritis cases will spur the VCF devices market.
4. The low risk of infection, short length of stay and quick recovery time of VCF treatment procedures will also drive market growth.
5. The risk of post-surgery complications and strict regulatory approvals will serve to the market’s detriment.
6. The balloon kyphoplasty devices segment will likely continue to dominate the market, with the vertebroplasty segment grow at a 6.1 percent CAGR through 2022.
7. North America led the global market in 2015, accounting for two-thirds share.
8. In 2015, Japan captured one-third of the Asia-Pacific VCF devices market.
9. Dominant market players include:
• Alphatec in Carlsbad, Calif.
• Benvenue Medical in Santa Clara, Calif.
• DePuy Synthes in Raynham, Mass.
• Globus Medical in Audubon, Pa.
• Medtronic in Dublin, Ireland
• Orthovita in Malvern, Pa.
• Osseon in Santa Rosa, Calif.
• Stryker Corp. in Kalamazoo, Mich.
• VEXIM in France
• Zimmer Biomet in Warsaw, Ind.
More articles on MIS:
5 key notes on morphine delivery during minimally invasive posterior lumbar fusion
20 things to know about minimally invasive spine surgery
5 key notes on MIS vs. open technologies for lumbar spinal fusion
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
